AU2003209459A8 - Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11 - Google Patents

Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11

Info

Publication number
AU2003209459A8
AU2003209459A8 AU2003209459A AU2003209459A AU2003209459A8 AU 2003209459 A8 AU2003209459 A8 AU 2003209459A8 AU 2003209459 A AU2003209459 A AU 2003209459A AU 2003209459 A AU2003209459 A AU 2003209459A AU 2003209459 A8 AU2003209459 A8 AU 2003209459A8
Authority
AU
Australia
Prior art keywords
bcmp
protein
human tumours
involving
interactions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003209459A
Other versions
AU2003209459A1 (en
Inventor
Pierre Legrain
Jonathan Alexander Terrett
Laurent Daviet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybrigenics SA
Oxford Glycosciences UK Ltd
Original Assignee
Hybrigenics SA
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrigenics SA, Oxford Glycosciences UK Ltd filed Critical Hybrigenics SA
Publication of AU2003209459A8 publication Critical patent/AU2003209459A8/en
Publication of AU2003209459A1 publication Critical patent/AU2003209459A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003209459A 2002-03-06 2003-03-06 Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11 Abandoned AU2003209459A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02290560.8 2002-03-06
EP02290560 2002-03-06
PCT/GB2003/000931 WO2003075014A2 (en) 2002-03-06 2003-03-06 Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11

Publications (2)

Publication Number Publication Date
AU2003209459A8 true AU2003209459A8 (en) 2003-09-16
AU2003209459A1 AU2003209459A1 (en) 2003-09-16

Family

ID=27771955

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003209459A Abandoned AU2003209459A1 (en) 2002-03-06 2003-03-06 Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11

Country Status (2)

Country Link
AU (1) AU2003209459A1 (en)
WO (1) WO2003075014A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
GB0616929D0 (en) * 2006-08-26 2006-10-04 Univ Liverpool Antibodies, assays and hybridomas
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004576D0 (en) * 2000-02-25 2000-04-19 Oxford Glycosciences Uk Ltd Proteins
AU3392901A (en) * 2000-02-25 2001-09-03 Oxford Glycosciences Uk Ltd Proteins

Also Published As

Publication number Publication date
AU2003209459A1 (en) 2003-09-16
WO2003075014A3 (en) 2003-12-24
WO2003075014A2 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
IL172316A0 (en) Novel compounds and their use in therapy
IL174994A0 (en) Pyrimidin - 4 - yl - 3, 4 - thione compounds and their use in therapy
AU2003293376A8 (en) Anti-angiogenic compounds and their use in cancer treatment
IL172826A0 (en) Quinoline derivates and their use in therapy
PT2702871T (en) Collagen biofabric and use thereof
IL166396A0 (en) Vanilloid receptor ligands and their use in treatments
IL165909A0 (en) Devices and methodologies useful in body aesthetics
AU2003262865A8 (en) Systems and methods for use in mobile medical training
EP1576093A4 (en) 3-deoxyglucosone and skin
IL182652A0 (en) Nitrobenzindoles and their use in cancer therapy
GB0615918D0 (en) Composition and its therapeutic use
GB0308382D0 (en) Therapeutic methods and means
AU2002346288A8 (en) Plypropylene fabric and its use in the personal care field
AU2003209459A8 (en) Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
SG110107A1 (en) Compound and use in treatment
SI1639013T1 (en) Pan-kir2dl NK-receptor antibodies and their use in diagnostic and therapy
GB0318546D0 (en) Quinoxalinones and their use
EP1582586A4 (en) Apoptosis-associated protein and use thereof
EP1701736A4 (en) Therapeutic agents and uses therefor
AU2003301759A8 (en) Human vps4a and vps4b functions in viral budding
GB0324205D0 (en) Piperidinyl-diarylsilanol compounds and their use in threrapy
GB0203043D0 (en) Benzimidazloe compounds their preparation and their use in therapy
GB0203042D0 (en) Anthraquinine compounds their preparation and their use in therapy
GB0325598D0 (en) Compound and use in treatment
GB0215773D0 (en) Compunds and their therapeutic use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase